Proteomic approach for the elucidation of biological defects in autism.
A 2001 rally cry said, "Look at brain proteins to find autism markers faster"—today’s RNA and MRI studies are answering that call with sharper tools.
01Research in Context
What this study did
The authors wrote a position paper. They argued that hunting for autism protein markers in donated brain tissue would be faster than classic gene-hunting.
They pictured labs scanning thousands of proteins at once. The hope was to spot clear chemical signatures of autism.
What they found
The paper is a call to action, not a lab report. It says, "Try proteomics" and warns the method will only catch the most common, water-friendly proteins.
How this fits with other research
McIntyre et al. (2017) took the idea but swapped brain tissue for living blood cells. They used RNA-seq instead of protein scans and added a new rule: split data by sex. Their tweak found stronger signals in girls, something the 2001 paper never tackled.
Ma et al. (2025) moved the hunt again—from molecules to MRI. They found a stable brain-pattern that separates ASD from typical brains and links to social scores. Their imaging marker is ready for multi-site use, while the 2001 protein plan is still theoretical.
Yao et al. (2025) meta-analysis covers 18 brain-stimulation trials. It shows the field has shifted from finding markers to testing treatments, something the 2001 paper did not address.
Why it matters
You probably won’t order a proteomic panel tomorrow. Still, the paper reminds us that biology can guide assessment. When you read new sex-split RNA studies or see MRI pattern claims, you’ll know they grew from this early protein idea. Keep an eye on multi-omics plus imaging—future assessments may blend both.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Pull up S et al. (2017) and note their sex-split data rule—check if any assessments you use report male vs female norms.
02At a glance
03Original abstract
Proteomic-based approaches, which examine expressed proteins in tissues or cells, have great potential in the elucidation of biological defects in heterogeneous neurodevelopmental disorders such as autism. In this approach, tissue or cellular proteins from control and affected subjects are separated on two-dimensional (2-D) polyacrylamide gel electrophoresis, and those proteins that show marked changes in the concentration between control and affected subjects are identified by mass spectroscopy. This method has been successfully applied in the elucidation of the molecular biological defect in classic late-infantile neuronal ceroid lipofuscinosis (Sleat et al., 1997). Unlike the classical methods of genome-wide screening for chromosomal localization followed by positional cloning, the proteomic approach requires limited number of tissue samples and the study can be completed in a relatively short time. Currently, these methods are available for relatively abundant proteins and generally are not applicable for hydrophobic proteins because 2-D gel electrophoresis is not very effective in the analysis of hydrophobic proteins. The genetic defect results in either total loss of proteins or changes in molecular weight and/or isoelectric point will be detectable by the proteomic method. Because autism is a neurogenetic disorder, brain is the tissue of choice for proteomic study. For an oligogenic disorder such as autism, at least some of the aberrant (genes) proteins may be identified by this technology.
Journal of autism and developmental disorders, 2001 · doi:10.1023/a:1013242910574